Government Approval of MDMA for Treating PTSD Likely
For the millions of Americans suffering from Posttraumatic Stress Disorder (PTSD), there may finally be a solution. A late-stage clinical trial of the psychedelic drug MDMA has shown great promise in treating the condition, making FDA approval likely in the next few years.
MDMA, an illegal drug commonly known as “ecstasy” or “molly” started out as a synthetic compound created in 1912. After a period of use in the treatment of mental health conditions, it escaped in the 1980s from the clinic to the dance floor and was criminalized by the FDA. But a few proponents continue to push for research, including Dr. Rick Doblin who founded the Multidisciplinary Association for Psychedelic Studies, or MAPS.
Decades later their efforts finally led to a green light from the FDA for clinical study. Since then, there have been three rigorous clinical trials, which have all shown enormous promise of the drug in combination with psychotherapy to treat PTSD.
Scientists Want to Know More About DMT Entities People Encounter
DMT is one of the most potent entheogens known to man, and the trip it induces is significantly different than other psychoactive substances. Users describe being transported to a distant realm where they meet seemingly autonomous entities, and often those same entities appear to different people. Now, researchers are attempting to catalog these experiences to figure out just what, or who, those DMT entities are.
DMT comes in more than one form and is an endogenous compound found in a multitude of plants, animals, and humans. Since it was synthesized in 1956 by Hungarian chemist Stephen Szara, it has baffled both users and researchers alike.
Recently, Dr. Roland Griffiths, a behavioral psychiatrist at Johns Hopkins University, published a questionnaire asking anyone who has taken DMT and met autonomous entities–beings that seem to act independently of one’s self–to provide details of their experience.